Abstract
Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.
Original language | English |
---|---|
Pages (from-to) | 319-327 |
Number of pages | 9 |
Journal | Journal of Gastrointestinal Oncology |
Volume | 4 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2013 |
Keywords
- Cetuximab
- Panitumumab
- Regorafenib